Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Medicina Clinica|September 28, 1991
[Rheumatoid arthritis and multiple neoplasms]J Ivorra, B Massutí, J Román, et al.
Oncology|January 1, 1989
Mitomycin-C and vinblastine in advanced breast cancerM Navarro, J Bellmunt, C Balañá, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 3, 2018
Correction to: SEOM clinical guidelines for anaplastic gliomas (2017)C Balañá, M Alonso, A Hernandez-Lain, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 24, 2017
SEOM clinical guidelines for anaplastic gliomas (2017)C Balañá, M Alonso, A Hernandez-Lain, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 30, 2018
2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primaryF Losa, L Iglesias, M Pané, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 3, 2015
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastomaJ M Sepúlveda, C Belda-Iniesta, M Gil-Gil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2005
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) studyA J González-Martín, E Calvo, I Bover, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 25, 2013
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in SpainC Balañá, M A Vaz, D Lopez, et al.
Pageof 1